A Systematic Review of Risk Prediction Models for Esophageal Adenocarcinoma in the General Population
Abstract
Background and Aims Risk prediction models can identify individuals at high risk of esophageal adenocarcinoma. This systematic review aimed to critically appraise the available models for projecting absolute risk of esophageal adenocarcinoma in the general population. Methods We searched Medline, Embase, and Cochrane Library databases for studies of risk prediction models for esophageal adenocarcinoma. Data were extracted from eligible studies according to the checklist for critical appraisal and data extraction for systematic reviews of prediction modelling studies. Risk of bias and applicability were assessed using the prediction model risk of bias assessment tool. Results We identified 7 studies. Age, sex, gastroesophageal reflux disease, body mass index, and tobacco smoking were the most common predictors. The area under the receiver operating characteristic curve ranged between 0.76 and 0.88 in the derivation datasets. The models based on 2 cohort studies showed good agreement between observed and predicted risks. All studies had at least 1 domain with high risk of bias, primarily attributable to methodological shortcomings in the data analysis. Conclusion Most risk prediction models showed good performance in identifying individuals at high risk of esophageal adenocarcinoma. Validation in external populations and cost-effectiveness evaluation are needed before these models can be applied in public health and clinical practice.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.